Glypican-1 nanoliposomes for potentiating growth factor activity in therapeutic angiogenesis.
Ontology highlight
ABSTRACT: Therapeutic angiogenesis is a highly appealing concept for treating tissues that become ischemic due to vascular disease. A major barrier to the clinical translation of angiogenic therapies is that the patients that are in the greatest need of these treatments often have long term disease states and co-morbidities, such as diabetes and obesity, that make them resistant to angiogenic stimuli. In this study, we identified that human patients with type 2 diabetes have reduced levels of glypican-1 in the blood vessels of their skin. The lack of this key co-receptor in the tissue may make the application of exogenous angiogenic growth factors or cell therapies ineffective. We created a novel therapeutic enhancer for growth factor activity consisting of glypican-1 delivered in a nanoliposomal ca
SUBMITTER: Monteforte AJ
PROVIDER: S-EPMC5600893 | biostudies-literature | 2016 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA